Type 1 diabetes is an autoimmune disease that destroys insulin production by pancreatic islet cells, leading to a chronic and challenging-to-manage disease. With 40,000 new cases annually, type 1 diabetes affects more than 1.25 million Americans, with peak diagnosis in children between the ages of 2 and 17. Up to 40 percent of new cases are diagnosed with potentially life-threatening conditions such as diabetic ketoacidosis. Autoantibody markers appear well in advance of symptoms, and pilot studies have shown that screening for these markers can reduce the rates of often-deadly diabetic ketoacidosis at diagnosis, reduce medical complications and potentially improve patients’ quality of life.


  • Screening using ultrasensitive and low-cost assays reduces incidence rates of DKA and can contribute to finding a cure.

  • Enable Biosciences’s ADAP assay for T1D was among the top performing assays in the world as presented at the Immunology of Diabetes Society (IDS) Congress in 2018.

  • Enable Biosciences has partnered with Hamilton Robotics to bring the improved assay to the Enable ADAP STAR platform, allowing for high-throughput population screening.

This product is available for Research and Clinical Diagnostics. We offer Clinical and Research Testing Services and Automated Workstations. Contact us at

Our Partners


Quick Facts

  • Type 1 diabetes is an autoimmune disease that affects 1-2 million Americans, mostly young children.

  • 40% of new cases are diagnosed with diabetic ketoacidosis, a potentially life-threatening condition. 

  • Autoantibody biomarkers appear years in advance of symptoms.

  • Testing for autoantibodies can reduce rates of medical complications and potentially improve quality of life.

  • Current tests are expensive, slow, or may miss critical diagnoses. 


  1. CDC National Diabetes Statistics Report, 2014.

  2. Diabetes Care 2017 Sep; 40(9): 1249-1255.

  3. Diabetes Care 2015 Jun; 38(6): 989-996.

  4. Diabetes Care 2003 Jan; 26(suppl 1): s33-s50.